Novartis 3Q Profit Drops Slightly; Sales Down on Pressure on Generics
Novartis 3Q Profit Drops Slightly; Sales Down on Pressure on Generics
Filed under: drug treatment news 2012
Novartis kept its 2012 full-year outlook unchanged for net sales in line with 2011 and core operating income margin in constant currencies to be slightly below 2011. "While net sales were … Novartis's second-biggest selling drug, Gleevec–used to …
Read more on Fox Business
QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to …
Filed under: drug treatment news 2012
As healthcare providers increasingly select the right drugs based on each individual's genomic information, the treatment of cancer is undergoing a revolution," said Dr. Helge Lubenow, Senior Vice President Molecular Diagnostics Business Area and …
Read more on Equities.com
Regeneron Reports Third Quarter 2012 Financial and Operating Results
Filed under: drug treatment news 2012
"With the recent approval of EYLEA in the United States for the treatment of macular edema following central retinal vein occlusion (CRVO), and the anticipated launch beginning by the end of this year in Japan, Australia, and Europe, we expect EYLEA to …
Read more on Sacramento Bee
More drug treatment news 2012 Resources
INVESTMENT PHILOSOPHY
Our final sentiment towards equities was slightly declining as a result of market erosion from generics; this continues to hurt pharmaceutical profits. Cypher Sales eroded by cheaper Boston Scientific stent. Net profit in This puts pressure on overall profit margins and, as a result, current P/E … Access Doc